Login / Signup

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.

Julius StraussJean-Laurent DevilleMario SznolAlain RavaudMarco MaruzzoRussell K PachynskiTheodore S GourdinMichele MaioLuc DirixJeffrey SchlomRenee N DonahueYo-Ting TsaiXiaoZhe WangYulia VugmeysterFrank BeierJoerg SeebeckAndreas SchroederSarah ChennoufiJames L Gulley
Published in: Journal for immunotherapy of cancer (2023)
M9241 plus avelumab was well tolerated at all DLs, including the dose-expansion part, with no new safety signals. However, the dose-expansion part did not meet the predefined efficacy criterion to proceed to stage 2.
Keyphrases
  • endothelial cells
  • clinical trial
  • phase iii
  • study protocol
  • induced pluripotent stem cells
  • phase ii
  • quality improvement